MARKER THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
MARKER THERAPEUTICS INC. - More news...
MARKER THERAPEUTICS INC. - More news...
- Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
- Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
- European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
- Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
- Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
- Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
- Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
- Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
- Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
- Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
- Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
- Marker Therapeutics Reports Q3 2022 Operating and Financial Results
- Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
- Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
- Marker Therapeutics Reports Q2 2022 Operating and Financial Results
- Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
- Marker Therapeutics Reports Q1 2022 Operating and Financial Results
- Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
